REG - Wellnex Life Limited - Appointment of Non-Executive Chair

Wellnex LifeAnnouncement

09/09/2025 07:30

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250909:nRSI5700Ya&default-theme=true

RNS Number : 5700Y  Wellnex Life Limited  09 September 2025

 

 

 

ASX/AIM
Announcement
9 September 2025

 

Wellnex Life Limited (ASX/AIM:WNX)

 

Appointment of Non-Executive Chair

 

 

Wellnex Life Limited ("Wellnex" or the "Company") (ASX:WNX  AIM:WNX) is
pleased to advise that the Board intends to appoint a new Non-Executive Chair.

 

Subject to this appointment, Mr. Andrew Vidler, who has served as Interim
Non-Executive Chairman over the past five months, will step down from this
role and continue to serve on the Board as an Independent Non-Executive
Director. The Board acknowledges and thanks Mr Vidler for his contribution
during this period.

 

The Board also welcomes the appointment of Ash Vesali as new Non-executive
Chairman, further enhancing the skills and experience available to guide the
Company through its next phase of growth. Mr Vesali's appointment is subject
to the completion of customary due diligence by the Company's Nominated
Advisor on AIM.

 

Mr Vesali brings over 20 years of global experience across high volume
manufacturing and top-tier consulting, supporting ASX executives and boards on
strategy, governance, performance improvement and business resiliency. He has
delivered operational excellence through governance reform and cost
restructuring and led turnarounds with disciplined capital allocation.
Additionally, he has driven growth through IP monetisation, international
expansion, and global strategic partnerships.

 

Mr Vesali commented: "I am excited about the opportunity ahead for Wellnex and
see it as my responsibility to further enhance confidence with our
shareholders. There is a clear pathway to further refine our strategy and
deliver value and I look forward to working with the Board to assist Wellnex
in delivering on its full potential."

 

The Board's immediate focus will be to continue leveraging the two core
pillars of the Company's strategy:

 

1.   Driving continued growth of Wellnex's category-leading consumer
brand Pain Away which holds Australia's number one position in natural
topical pain relief with an estimated 14% market share.

 

2.   Continued expansion of our contract manufacturing partnerships in the
softgel analgesics market where the Company already holds supply agreements
with leading pharmaceutical brands such as UK giant Haleon.

 

A further announcement containing the requisite information under paragraph
(g) of Schedule Two of the AIM Rules regarding Mr Vesali will be made
following completion of Nominated Adviser due diligence and his appointment to
the Board.

 

This ASX/AIM announcement has been authorised by the Board of Wellnex Life
Limited (ASX/AIM:WNX).

 

For further information, please contact:

 

Wellnex Life Limited (ASX:WNX)
                                 Reach Markets

Zack Bozinovski
                     T: 1300 805 795

Chief Executive Officer & Managing Director                   E:
IR@reachmarkets.com.au (mailto:IR@reachmarkets.com.au)

P: +61 3 8399 9419

E: zack.b@wellnexlife.com.au (mailto:zack.b@wellnexlife.com.au)

 

UK Investors

 

Strand Hanson (Financial & Nominated Advisor)

James Harris / Richard Johnson
                          Tel: +44 (0) 20 7409 3494

 

Orana Corporate LLP (Joint
Broker)                                 swykeham@oranacorp.com
(mailto:swykeham@oranacorp.com)

Sebastian Wykeham

 

S.P. Angel Corporate Finance LLP (Joint Broker)            Tel: +44
(0)20 3470 0470

David Hignell / Vadim Alexandre

 

 

To learn more, please visit: www.Wellnex Lifelife.com.au/
(https://wellnexlife.com.au/)

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOAQKLBBEKLLBBL